Evaluation of CYP3A-mediated drug-drug interactions with romidepsin in patients with advanced cancer. - Wikidata - awgldk - TriplyDB

Evaluation of CYP3A-mediated drug-drug interactions with romidepsin in patients with advanced cancer.

Evaluation of CYP3A-mediated drug-drug interactions with romidepsin in patients with advanced cancer.

http://www.wikidata.org/entity/Q33423486

about

Pharmacokinetic Interaction of Rifampicin with Oral Versus Intravenous Anticancer Drugs: Challenges, Dilemmas and Paradoxical Effects Due to Multiple Mechanisms The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo No Increased Risk of Ketoconazole Toxicity in Drug-Drug Interaction Studies.

P2860

Q26751444-98E476E2-A5ED-49C9-A2FD-F848211536D0 Q35778783-8D485269-2D41-49E0-BF46-9CFEBCC125E5 Q38894543-FEC1E90A-0344-4846-9D43-477681DEC79C

P2860

Evaluation of CYP3A-mediated drug-drug interactions with romidepsin in patients with advanced cancer.

http://www.wikidata.org/entity/Q33423486

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Evaluation of CYP3A-mediated d ...... patients with advanced cancer.

@ast

Evaluation of CYP3A-mediated d ...... patients with advanced cancer.

@en

type

label

Evaluation of CYP3A-mediated d ...... patients with advanced cancer.

@ast

Evaluation of CYP3A-mediated d ...... patients with advanced cancer.

@en

prefLabel

Evaluation of CYP3A-mediated d ...... patients with advanced cancer.

@ast

Evaluation of CYP3A-mediated d ...... patients with advanced cancer.

@en

P1433

Q33423486-795727FD-7DE9-4129-BB3A-51F4F7F62CEE

P1476

Q33423486-70DEEA7B-1FBC-40AD-AD81-B82AB377E5F8

P2093

Q33423486-4C98B715-45E8-4644-8226-144814D2DF59

Q33423486-66614B01-C2AC-435D-87DB-972576027DEF

Q33423486-812996E0-29D9-4F38-A046-7B04E6DBC567

Q33423486-8A230DD7-961B-4D0D-A4D7-9DCE4B2C66DF

Q33423486-A848438A-03AB-4DE4-9CB6-A3DEA06E8E55

Q33423486-D0BBF87C-C7AB-4787-B7C6-AE8624AAE055

Q33423486-E91BAEB6-28DA-4D3C-8102-649A92C0EBDA

P2860

Q33423486-02E7D1D8-D7C5-492B-9D8A-45F3F3EA9C42

Q33423486-09958C59-1025-4971-B9F0-8CFF7861A3CF

Q33423486-09BCCCAD-3423-4B53-B3B6-1D5C0973B89D

Q33423486-0DCB72BA-DD13-4049-B387-A14A8775EB44

Q33423486-21280575-B217-421A-9250-74B8AF0E42D1

Q33423486-25152853-5DA5-4C95-93F3-144194848347

Q33423486-32129A6F-FD0A-4368-B39C-8D03F43BBD9F

Q33423486-376A9622-DF88-4949-967C-2AD1BA2A3C65

Q33423486-4889E382-B2C2-4F5D-9B0F-4CFB7E5B2C8D

Q33423486-49ED2DC1-D285-46B7-A3A6-F9FAD5026429

P304

Q33423486-65D2A4AE-6342-4E6B-A367-F3B661007B3C

P31

Q33423486-1A1D353D-6C46-49D9-BDB9-A44295C5BC9D

P356

Q33423486-79FFAA32-84A5-4718-97CE-47472124F896

P433

Q33423486-AD1F48F7-56DE-4027-AB96-81A8E7E5E21F

P478

Q33423486-5B132273-FC83-48A9-A2D8-8D8D505C74B9

P50

Q33423486-D6D6A167-4B60-4E72-B047-69B1AA0AB319

P577

Q33423486-BB00CB53-7D8F-4CB7-B6F1-FB44DEDB76B5

P698

Q33423486-D25A5D18-FD71-4C49-BFAB-38D432FB23B9

P932

Q33423486-CA2AEEA4-2494-479E-8F17-5A6EB6047601

P356

P1433

The Journal of Clinical Pharmacology

P1476

Evaluation of CYP3A-mediated d ...... patients with advanced cancer.

@en

P2093

Eric Laille

http://www.w3.org/2001/XMLSchema#string

Hendrik-Tobias Arkenau

http://www.w3.org/2001/XMLSchema#string

Howard A Burris

http://www.w3.org/2001/XMLSchema#string

Jeffrey Infante

http://www.w3.org/2001/XMLSchema#string

Liangang Liu

http://www.w3.org/2001/XMLSchema#string

Manish Patel

http://www.w3.org/2001/XMLSchema#string

Suzanne F Jones

http://www.w3.org/2001/XMLSchema#string

P2860

The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions

Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation

Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.

A phase I trial of depsipeptide (FR901228) in patients with advanced cancer.

FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor.

PXR, CAR and drug metabolism.

Complex drug interactions of the HIV protease inhibitors 3: effect of simultaneous or staggered dosing of digoxin and ritonavir, nelfinavir, rifampin, or bupropion

Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma

Romidepsin: a novel histone deacetylase inhibitor for cancer.

Romidepsin: a histone deacetylase inhibitor for refractory cutaneous T-cell lymphoma.

P304

1378-1385

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JCPH.560

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P50

Charlotte Lemech

P577

2015-06-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26053962

http://www.w3.org/2001/XMLSchema#string

P932

5034805

http://www.w3.org/2001/XMLSchema#string